COBRA™: a highly potent conditionally active T cell engager engineered for the treatment of solid tumors

References

• Yu B, Liu D. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma. J Hematol Oncol. 2019;12:94. doi:https://doi.org/10.1186/s13045-019-0786-6.
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. NE J Med. 2010;363:1812–11. doi:https://doi.org/10.1056/NEJMoa1002965.
   PubMed Web of Science ®Google Scholar
• Tabasinezhad M, Talebkhan Y, Wenzel W, Rahimi H, Omidinia E, Mahboudi F. Trends in therapeutic antibody affinity maturation: from in-vitro towards next-generation sequencing approaches. Immunol Lett. 2019;212:106–13. doi:https://doi.org/10.1016/j.imlet.2019.06.009.
   PubMed Web of Science ®Google Scholar
• Peters C, Brown S. Antibody-drug conjugates as novel anti-cancer chemotherapeutics. Bioscience Rep. 2015;35(4):e00225. doi:https://doi.org/10.1042/BSR20150089.
   Google Scholar
• Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, Wu HC. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1. doi:https://doi.org/10.1186/s12929-019-0592-z.
   PubMed Web of Science ®Google Scholar
• Lo KM, Leger O, Hock B. Antibody Engineering. Microbiol Spect. 2014;2:AID–0007. doi:https://doi.org/10.1128/microbiolspec.AID-0007-12.
   PubMedGoogle Scholar
• Shim H. Bispecific antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomolecules. 2020;10:360. doi:https://doi.org/10.3390/biom10030360.
   PubMed Web of Science ®Google Scholar
• Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007;67(24):11991–99. doi:https://doi.org/10.1158/0008-5472.CAN-07-2068.
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev. 2010;236:265–75. doi:https://doi.org/10.1111/j.1600-065X.2010.00910.x.
   PubMed Web of Science ®Google Scholar
• Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95:3900–08. doi:https://doi.org/10.1182/blood.V95.12.3900.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–58. doi:https://doi.org/10.1182/blood.V99.3.754.
   PubMed Web of Science ®Google Scholar
• Jitschin R, Saul D, Braun M, Tohumeken S, Volkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D. CD33/CD3-bispecific T-cell engaging (BiTE) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer. 2018;6:116. doi:https://doi.org/10.1186/s40425-018-0432-9.
   PubMed Web of Science ®Google Scholar
• Huehls AM, Coupet TA, Sentman CL. Bispecific T-cell engagers for cancer immunotherapy. Immunol Cell Biol. 2015;93:290–96. doi:https://doi.org/10.1038/icb.2014.93.
   PubMed Web of Science ®Google Scholar
• Fu M, He Q, Guo Z, Zhou X, Li H, Zhao L, Tang H, Zhou X, Zhu H, Shen G, et al. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor. Front Immunol. 2019;10:1396. doi:https://doi.org/10.3389/fimmu.2019.01396.
   PubMed Web of Science ®Google Scholar
• Dreier T, Baeuerle PA, Fichtner I, Grun M, Schlereth B, Lorenczewski G, Kufer P, Lutterbuse R, Reithmuller G, Gjorstrup P, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct. J Immunol (Baltimore, Md. 1950;2003(170):4397–402.
   Google Scholar
• Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8:104. doi:https://doi.org/10.1186/s13045-015-0195-4.
   PubMed Web of Science ®Google Scholar
• Goebeler ME, Bargou R. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma. 2016;57:1021–32. doi:https://doi.org/10.3109/10428194.2016.1161185.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (New York, NY). 2008;321:974–77. doi:https://doi.org/10.1126/science.1158545.
   Google Scholar
• Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO. Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res. 1998;4:2669–76.
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mole Ther. 2011;19:620–26. doi:https://doi.org/10.1038/mt.2010.272.
   PubMed Web of Science ®Google Scholar
• Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. 2008;105:8061–66. doi:https://doi.org/10.1073/pnas.0710929105.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323–37. doi:https://doi.org/10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421–34. doi:https://doi.org/10.1016/j.addr.2008.04.012.
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006;6:583–92. doi:https://doi.org/10.1038/nrc1893.
   PubMed Web of Science ®Google Scholar
• Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50:814s–9s.
   PubMed Web of Science ®Google Scholar
• Webb BA, Chimenti M, Jacobson MP, Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11:671–77. doi:https://doi.org/10.1038/nrc3110.
   PubMed Web of Science ®Google Scholar
• Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6:15–19. doi:https://doi.org/10.1016/S1357-4310(99)01615-9.
   PubMedGoogle Scholar
• Pillai SR, Damaghi M, Marunaka Y, Spugnini EP, Fais S, Gillies RJ. Causes, consequences, and therapy of tumors acidosis. Cancer Metastasis Rev. 2019;38:205–22. doi:https://doi.org/10.1007/s10555-019-09792-7.
   PubMed Web of Science ®Google Scholar
• Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckland, NZ). 2015;3:83–92.
   PubMed Web of Science ®Google Scholar
• Moulder JE, Rockwell S. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev. 1987;5:313–41. doi:https://doi.org/10.1007/BF00055376.
   PubMed Web of Science ®Google Scholar
• Engin K, Leeper DB, Cater JR, Thistlethwaite AJ, Tupchong L, McFarlane JD. Extracellular pH distribution in human tumours. Int J Hyperther. 1995;11:211–16. doi:https://doi.org/10.3109/02656739509022457.
   PubMed Web of Science ®Google Scholar
• Rakashanda S, Rana F, Rafiq S, Masood A, Amin S. Role of proteases in cancer: A review. Biotechnol Mole Biol Rev. 2012;7:90–101. doi:https://doi.org/10.5897/BMBR11.027.
   Google Scholar
• DeClerck YA, Mercurio AM, Stack MS, Chapman HA, Zutter MM, Muschel RJ, Raz A, Matrisian LM, Sloane BF, Noel A, et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol. 2004;164:1131–39. doi:https://doi.org/10.1016/S0002-9440(10)63200-2.
   PubMed Web of Science ®Google Scholar
• Zhou F, Fu T, Huang Q, Kuai H, Mo L, Liu H, Wang Q, Peng Y, Han D, Zhao Z, et al. Hypoxia-activated PEGylated conditional aptamer/antibody for cancer imaging with improved specificity. J Am Chem Soc. 2019;141:18421–27. doi:https://doi.org/10.1021/jacs.9b05063.
   PubMed Web of Science ®Google Scholar
• Sharp L, Chang C, Frey G, Liu H, Xing C, Wang J, Walls M, Wheeler C, Ben Y, Boyle WJ, et al. Potent CAB CTLA4 antibody to reduce immune side effects and toxicities associated with single-agent and combination cancer immuno therapies. Cancer Res. 2019;79:2708.
   Web of Science ®Google Scholar
• Chang C, Frey G, Sharp L, Boyle WJ, Wang J, Xing C, Liu H, Wheeler C, Walls M, Short JM. Novel conditionally active biologic (CAB) antibody targeting EpCAM demonstrates anti-tumor efficacy in vivo. Cancer Res. 2019;79:356.
   Web of Science ®Google Scholar
• Minogue E, Millar D, Chuan Y, Zhang S, Grauwet K, Guo M, Langenbucher A, Benes CH, Heather J, Minshull J, et al. Redirecting T-cells against AML in a multidimensional targeting space using T-cell engaging antibody circuits (TEAC). Blood. 2019;134:2653. doi:https://doi.org/10.1182/blood-2019-127634.
   Web of Science ®Google Scholar
• Boustany LM, Wong L, White CW, Diep L, Huang Y, Liu S, Richardson JH, Kavanaugh WM, Irving BA. EGFR-CD3 bispecific probody therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies. Mole Cancer Ther. 2018;17:A164–A.
   Web of Science ®Google Scholar
• Ellerman D. Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods (San Diego, Calif). 2019;154:102–17. doi:https://doi.org/10.1016/j.ymeth.2018.10.026.
   PubMed Web of Science ®Google Scholar
• Waas ET, Lomme RM, DeGroot J, Wobbes T, Hendriks T. Tissue levels of active matrix metalloproteinase-2 and −9 in colorectal cancer. British J Cancer. 2002;86:1876–83. doi:https://doi.org/10.1038/sj.bjc.6600366.
   PubMed Web of Science ®Google Scholar
• Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67. doi:https://doi.org/10.1016/j.cell.2010.03.015.
   PubMed Web of Science ®Google Scholar
• Kato K, Hara A, Kuno T, Kitaori N, Huilan Z, Mori H, Toida M, Shibata T. Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity. J Cancer Res Clin Oncol. 2005;131(6):340–46. doi:https://doi.org/10.1007/s00432-004-0654-8.
   PubMed Web of Science ®Google Scholar
• Edwards JG, McLaren J, Jones JL, Waller DA, O’Byrne KJ. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 2003;88:1553–59. doi:https://doi.org/10.1038/sj.bjc.6600920.
   PubMed Web of Science ®Google Scholar
• Sven H, Ingrid O, Judith B, Maria S-M. Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies. Antibodies. 2015;4:141–56. doi:https://doi.org/10.3390/antib4030141.
   Google Scholar
• Andersen JT, Dalhus B, Cameron J, Daba MB, Plumridge A, Evans L, Brennan SO, Gunnarsen KS, Bjoras M, Sleep D, et al. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor. Nat Comm. 2012;3:610. doi:https://doi.org/10.1038/ncomms1607.
   PubMed Web of Science ®Google Scholar
• Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, Sekimori Y, Orita T, Aso Y, Hattori K, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng Des Sel. 2010;23:667–77. doi:https://doi.org/10.1093/protein/gzq034.
   PubMed Web of Science ®Google Scholar
• Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science (New York, NY). 2014;346:256–59. doi:https://doi.org/10.1126/science.1256930.
   Google Scholar
• Yuan Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harbor Perspect Med. 2016;6:a026583. doi:https://doi.org/10.1101/cshperspect.a026583.
   Google Scholar
• Ramon y Cajal S, Sese  M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, Hernández-Losa J, Castellví J. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mole Med (Berlin, Germany). 2020;98:161–77. doi:https://doi.org/10.1007/s00109-020-01874-2.
   PubMed Web of Science ®Google Scholar
• Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, Slager S, Fonseca R, Shanafelt T, Kay N, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014;28(12):2395–98. doi:https://doi.org/10.1038/leu.2014.226.
   PubMed Web of Science ®Google Scholar
• Caswell-Jin JL, McNamara K, Reiter JG, Sun R, Hu Z, Ma Z, Ding J, Suarez CJ, Tilk S, Raghavendra A, et al. Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy. Nat Comm. 2019;10(1):657. doi:https://doi.org/10.1038/s41467-019-08593-4.
   PubMed Web of Science ®Google Scholar
• Aleksakhina SN, Kashyap A, Imyanitov EN. Mechanisms of acquired tumor drug resistance. Biochim Et Biophys Acta Rev Cancer. 2019;1872:188310. doi:https://doi.org/10.1016/j.bbcan.2019.188310.
   PubMed Web of Science ®Google Scholar